American Century Companies Inc. Buys 369,160 Shares of Catalyst Pharmaceuticals, Inc. $CPRX

Key Points

• American Century Companies Inc. significantly increased its stake in Catalyst Pharmaceuticals by 234.5%, acquiring 369,160 additional shares and now owning a total of 526,569 shares valued at approximately $12.77 million.
• Institutional investors collectively hold 79.22% of Catalyst Pharmaceuticals, with notable recent investments including Castlekeep Investment Advisors acquiring a stake worth $37.49 million.
• Several analysts have recently given mixed ratings on Catalyst Pharmaceuticals, with Cantor Fitzgerald upgrading the stock to a "strong-buy" while others downgraded it to "hold," leading to an overall average rating of "Buy" with a target price of $33.20.

American Century Companies Inc. lifted its position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX - Free Report) by 234.5% during the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 526,569 shares of the biopharmaceutical company's stock after buying an additional 369,160 shares during the period. American Century Companies Inc. owned about 0.43% of Catalyst Pharmaceuticals worth $12,769,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Park Square Financial Group LLC bought a new position in shares of Catalyst Pharmaceuticals in the fourth quarter worth approximately $29,000. Sound Income Strategies LLC bought a new position in shares of Catalyst Pharmaceuticals in the first quarter worth approximately $64,000. GAMMA Investing LLC lifted its stake in shares of Catalyst Pharmaceuticals by 26.2% in the first quarter. GAMMA Investing LLC now owns 2,791 shares of the biopharmaceutical company's stock worth $68,000 after buying an additional 579 shares in the last quarter. Quarry LP bought a new position in shares of Catalyst Pharmaceuticals in the fourth quarter worth approximately $104,000. Finally, PNC Financial Services Group Inc. lifted its stake in shares of Catalyst Pharmaceuticals by 57.2% in the first quarter. PNC Financial Services Group Inc. now owns 5,501 shares of the biopharmaceutical company's stock worth $133,000 after buying an additional 2,002 shares in the last quarter. Institutional investors own 79.22% of the company's stock.

Insider Buying and Selling at Catalyst Pharmaceuticals

In other news, insider Steve Miller sold 115,000 shares of the stock in a transaction that occurred on Tuesday, August 26th. The shares were sold at an average price of $20.28, for a total value of $2,332,200.00. Following the transaction, the insider owned 949,663 shares in the company, valued at $19,259,165.64. This represents a 10.80% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Richard J. Daly sold 22,970 shares of the stock in a transaction that occurred on Tuesday, August 26th. The stock was sold at an average price of $20.62, for a total transaction of $473,641.40. Following the completion of the transaction, the chief executive officer owned 226,794 shares in the company, valued at $4,676,492.28. This trade represents a 9.20% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 167,894 shares of company stock worth $3,434,690 over the last quarter. Company insiders own 10.40% of the company's stock.

Catalyst Pharmaceuticals Stock Performance

Shares of CPRX stock traded up $0.21 during trading hours on Friday, reaching $20.59. The company had a trading volume of 814,373 shares, compared to its average volume of 1,497,881. The business has a fifty day moving average price of $21.02 and a 200-day moving average price of $22.51. Catalyst Pharmaceuticals, Inc. has a one year low of $19.00 and a one year high of $26.58. The firm has a market cap of $2.52 billion, a PE ratio of 12.48, a price-to-earnings-growth ratio of 0.84 and a beta of 0.85.

Analyst Ratings Changes

CPRX has been the topic of several analyst reports. Cantor Fitzgerald upgraded shares of Catalyst Pharmaceuticals to a "strong-buy" rating in a research note on Thursday, June 5th. Wall Street Zen downgraded shares of Catalyst Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Saturday, August 9th. Finally, Zacks Research lowered shares of Catalyst Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research note on Tuesday, August 19th. Two research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of "Buy" and an average price target of $33.20.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.